{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:41:39Z","timestamp":1759333299699},"reference-count":52,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,20]]},"DOI":"10.18632\/oncotarget.12441","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T18:28:35Z","timestamp":1475605715000},"page":"84246-84257","source":"Crossref","is-referenced-by-count":10,"title":["Generation of V \u03b113\/\u03b221+T cell specific target CML cells by TCR gene transfer"],"prefix":"10.18632","volume":"7","author":[{"given":"Xianfeng","family":"Zha","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, China"},{"name":"Institute of Hematology, Jinan University, Guangzhou, China"},{"name":"Department of Chemistry, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijian","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Jinan University, Guangzhou, China"},{"name":"Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China"},{"name":"Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,4]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1054\/blre.1999.0119","article-title":"Biology of BCR-ABL","volume":"13","author":"Elefanty","year":"1999","journal-title":"Blood Rev"},{"key":"2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Talpaz","year":"2001","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Kaeda","year":"2008","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.18632\/oncotarget.2278","article-title":"Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy","volume":"5","author":"Los","year":"2014","journal-title":"Oncotarget"},{"key":"5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Baccarani","year":"2007","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-015-0207-4","article-title":"Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood\u2014a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation","volume":"8","author":"Santasusana","year":"2015","journal-title":"J Hematol Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/107327480901600206","article-title":"The biological basis for immunotherapy in patients with chronic myelogenous leukemia","volume":"16","author":"Dubovsky","year":"2009","journal-title":"Cancer control"},{"key":"8","first-page":"404081","article-title":"Improving TCR Gene Therapy for Treatment of Haematological Malignancies","volume":"2012","author":"Stauss","year":"2012","journal-title":"Adv Hematol"},{"key":"9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mam.2006.12.006","article-title":"Redirecting T lymphocyte specificity by T cell receptor gene transfer\u2014a new era for immunotherapy","volume":"28","author":"Uckert","year":"2007","journal-title":"Mol Aspects Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Scheibenbogen","year":"2009","journal-title":"Blood"},{"key":"11","first-page":"716926","article-title":"Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector","volume":"2011","author":"Sun","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"12","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.18632\/oncotarget.7044","article-title":"Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-8722-7-3","article-title":"Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury","volume":"7","author":"Shiku","year":"2014","journal-title":"J Hematol Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.humimm.2011.06.015","article-title":"Characterization of the CDR3 structure of the Vbeta21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia","volume":"72","author":"Li","year":"2011","journal-title":"Hum Immunol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Savoldo","year":"2008","journal-title":"Blood"},{"key":"16","first-page":"1112","article-title":"[Establishment of stable subline of K562 cells expressing human leucocyte antigen a1101]","volume":"19","author":"Li","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12185-013-1493-7","article-title":"Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors","volume":"99","author":"Fujiwara","year":"2014","journal-title":"Int J Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2011-02-337089","article-title":"Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety","volume":"118","author":"Yasukawa","year":"2011","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-4-2","article-title":"Generation of diffuse large B cell lymphoma-associated antigen-specific Valpha6\/Vbeta13+T cells by TCR gene transfer","volume":"4","author":"Li","year":"2011","journal-title":"J Hematol Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/10428190109097706","article-title":"BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia","volume":"42","author":"Christmas","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00262-002-0362-7","article-title":"The abl\/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl\/bcr can be recognized by both CD4+ and CD8+ T lymphocytes","volume":"52","author":"Pawelec","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Langlade-Demoyen","year":"1998","journal-title":"J Clin Invest"},{"key":"23","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00262-009-0703-x","article-title":"BCR\/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors","volume":"58","author":"Dodi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.V91.3.977","article-title":"Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia","volume":"91","author":"Juji","year":"1998","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","article-title":"Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primaryimmunization with a BCR-ABL breakpoint peptide","volume":"88","author":"Leeksma","year":"1996","journal-title":"Blood"},{"key":"26","first-page":"3355","article-title":"CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner","volume":"92","author":"Fujita","year":"1998","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/0167-5699(95)80082-4","article-title":"Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses","volume":"16","author":"Parmiani","year":"1995","journal-title":"Immunol Today"},{"key":"28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jim.2006.09.015","article-title":"Standardized analysis for the quantification of Vbeta CDR3 T-cell receptor diversity","volume":"317","author":"Bonyhadi","year":"2006","journal-title":"J Immunol Methods"},{"key":"29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2249.2008.03842.x","article-title":"Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases","volume":"155","author":"Toma","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"30","doi-asserted-by":"publisher","first-page":"40337","DOI":"10.18632\/oncotarget.5378","article-title":"Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study","volume":"6","author":"Xi","year":"2015","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10245330500226662","article-title":"The TCR Vbeta repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen","volume":"10","author":"Wu","year":"2005","journal-title":"Hematology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s11427-015-4930-4","article-title":"Characteristics of the TCR Vbeta repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations","volume":"58","author":"Li","year":"2015","journal-title":"Sci China Life Sci"},{"key":"33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-2-12","article-title":"Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines","volume":"2","author":"Wolchok","year":"2004","journal-title":"J Transl Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1172\/JCI83465","article-title":"Targeting human melanoma neoantigens by T cell receptor gene therapy","volume":"126","author":"Blankenstein","year":"2016","journal-title":"J Clin Invest"},{"key":"35","doi-asserted-by":"publisher","first-page":"25356","DOI":"10.18632\/oncotarget.4516","article-title":"CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer","volume":"6","author":"Roldan","year":"2015","journal-title":"Oncotarget"},{"key":"36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.molimm.2014.12.009","article-title":"Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic","volume":"67","author":"Darcy","year":"2015","journal-title":"Mol Immunol"},{"key":"37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1242\/dmm.018036","article-title":"Genetically modified T cells in cancer therapy: opportunities and challenges","volume":"8","author":"Mount","year":"2015","journal-title":"Dis Model Mech"},{"key":"38","doi-asserted-by":"crossref","first-page":"e68201","DOI":"10.1371\/journal.pone.0068201","article-title":"Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer","volume":"8","author":"Qasim","year":"2013","journal-title":"PLoS One"},{"key":"39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/mt.2016.51","article-title":"Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon\/Transposase System","volume":"24","author":"Rosenberg","year":"2016","journal-title":"Mol Ther"},{"key":"40","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1182\/blood-2015-11-629071","article-title":"Optimizing T-cell receptor gene therapy for hematologic malignancies","volume":"127","author":"Stauss","year":"2016","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.4049\/jimmunol.0902047","article-title":"Selected murine residues endow human TCR with enhanced tumor recognition","volume":"184","author":"Cohen","year":"2010","journal-title":"J Immunol"},{"key":"42","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.4049\/jimmunol.0902055","article-title":"Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells","volume":"184","author":"Uckert","year":"2010","journal-title":"J Immunol"},{"key":"43","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.4049\/jimmunol.180.11.7736","article-title":"Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer","volume":"180","author":"Debets","year":"2008","journal-title":"J Immunol"},{"key":"44","doi-asserted-by":"publisher","first-page":"51581","DOI":"10.18632\/oncotarget.9955","article-title":"Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform","volume":"7","author":"Biagi","year":"2016","journal-title":"Oncotarget"},{"key":"45","doi-asserted-by":"publisher","first-page":"21199","DOI":"10.18632\/oncotarget.8385","article-title":"An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells","volume":"7","author":"Theobald","year":"2016","journal-title":"Oncotarget"},{"key":"46","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1158\/0008-5472.CAN-15-1742","article-title":"Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory","volume":"76","author":"Ito","year":"2016","journal-title":"Cancer Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2009.03227.x","article-title":"Molecular immunology lessons from therapeutic T-cell receptor gene transfer","volume":"129","author":"Morris","year":"2010","journal-title":"Immunology"},{"key":"48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"49","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.18632\/oncotarget.8385","article-title":"Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"50","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Lee","year":"2016","journal-title":"Nat Commun"},{"key":"51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Riviere","year":"2013","journal-title":"Cancer Discov"},{"key":"52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00365.x","article-title":"The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes","volume":"158","author":"Kobori","year":"2009","journal-title":"Br J Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T13:31:09Z","timestamp":1596720669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,4]]},"references-count":52,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12,20]]}},"alternative-id":["12441","27713165"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12441","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,4]]}}}